After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its hi | Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma, a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its high-stakes first-line readout.